Intercept Pharma (ICPT) reported Q3 EPS of ($3.04), $2.22 worse than the analyst estimate of ($0.82). Revenue for the quarter came in at $77.6 million versus the consensus estimate of $73.74 million.
2022 Financial Guidance
We are updating our full year 2022 guidance:
- Increasing Ocaliva non-GAAP adjusted net sales guidance to $340 million to $350 million from $325 million to $345 million.
- Narrowing non-GAAP adjusted operating expense guidance to $350 million to $365 million from $335 million to $365 million.
- This guidance includes our international business for the first six months of the year and our ongoing U.S. business for the full year.